US7078383B2
(en)
*
|
1988-09-02 |
2006-07-18 |
Dyax Corp. |
ITI-D1 Kunitz domain mutants as HNE inhibitors
|
US20060134087A1
(en)
*
|
1988-09-02 |
2006-06-22 |
Dyax Corp. |
ITI-D1 Kunitz domain mutants as hNE inhibitors
|
ES2113940T3
(es)
*
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
PT737207E
(pt)
*
|
1994-01-11 |
2005-02-28 |
Dyax Corp |
Inibidores de plasmina humana derivados de dominios kunitz
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
DK0744958T3
(da)
|
1994-01-31 |
2003-10-20 |
Univ Boston |
Polyklonale antistofbiblioteker
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
US6010861A
(en)
*
|
1994-08-03 |
2000-01-04 |
Dgi Biotechnologies, Llc |
Target specific screens and their use for discovering small organic molecular pharmacophores
|
US5780265A
(en)
*
|
1995-06-05 |
1998-07-14 |
Genentech, Inc. |
Kunitz type plasma kallikrein inhibitors
|
US5786328A
(en)
*
|
1995-06-05 |
1998-07-28 |
Genentech, Inc. |
Use of kunitz type plasma kallikrein inhibitors
|
US20030199450A1
(en)
*
|
2001-04-27 |
2003-10-23 |
Chiron Corporation |
Regulation of cytokine synthesis and release
|
US6242414B1
(en)
*
|
1995-06-07 |
2001-06-05 |
Chiron Corporation |
Regulation of cytokine synthesis and release
|
PT891426E
(pt)
*
|
1996-03-11 |
2006-10-31 |
Bayer Corp |
Bicunina humana
|
US5876925A
(en)
*
|
1996-10-11 |
1999-03-02 |
The Trustees Of The University Of Pennsylvania |
Magnetically activated cell sorting for production of proteins
|
US5985543A
(en)
|
1996-10-11 |
1999-11-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for detection of antibody binding to cells
|
AU6042298A
(en)
|
1997-01-31 |
1998-08-25 |
Human Genome Sciences, Inc. |
Tissue factor pathway inhibitor-3
|
WO1999055365A1
(en)
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
WO1999063090A2
(en)
*
|
1998-06-03 |
1999-12-09 |
Scios, Inc. |
Protease inhibitor peptides
|
AU5122499A
(en)
|
1998-07-27 |
2000-02-21 |
Genentech Inc. |
Improved transformation efficiency in phage display through modification of a coat protein
|
WO2000015823A1
(en)
|
1998-09-11 |
2000-03-23 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
EP1374891B1
(de)
*
|
1998-12-22 |
2008-09-10 |
Bayer Aktiengesellschaft |
Methode zur Beschleunigung der Schleimauflöserate
|
US20070140979A1
(en)
*
|
1998-12-22 |
2007-06-21 |
Bayer Aktiengesellschaft |
Method for accelerating the rate of mucociliary clearance
|
US6294648B1
(en)
*
|
1999-07-20 |
2001-09-25 |
Bayer Corporation |
Protein having proteinase inhibitor activity
|
AU784983B2
(en)
*
|
1999-12-15 |
2006-08-17 |
Genentech Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
WO2001092549A2
(en)
*
|
2000-05-31 |
2001-12-06 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
US20020150594A1
(en)
*
|
2000-06-26 |
2002-10-17 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
EP1184393A1
(de)
*
|
2000-09-04 |
2002-03-06 |
Debiopharm S.A. |
Verfahren zur Reinigung von EPI-HNE Proteinen
|
US6989438B2
(en)
|
2000-09-04 |
2006-01-24 |
Debiopharm S.A. |
Process for the purification of EPI-HNE proteins
|
CA2426992A1
(en)
*
|
2000-10-31 |
2002-05-10 |
Debiopharm S.A. |
Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
|
EP1201249A1
(de)
*
|
2000-10-31 |
2002-05-02 |
Debiopharm S.A. |
Suspension von EPI-HNE-4, daraus hergestelltes Trockenpulveraerosol, Herstellungsverfahren und Arzneimittel enthaltend diese Suspension- oder Aerosolzubereitung und ihre Verwendung
|
US20060223114A1
(en)
*
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
US20050048512A1
(en)
*
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
US20040175756A1
(en)
*
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
CA2444854A1
(en)
*
|
2001-04-26 |
2002-11-07 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20030157561A1
(en)
*
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
US20050053973A1
(en)
*
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
EP1992643A3
(de)
|
2001-06-20 |
2008-12-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
WO2003024392A2
(en)
|
2001-09-18 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003088808A2
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP1575571A4
(de)
|
2002-01-02 |
2008-06-25 |
Genentech Inc |
Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
|
AU2003210220A1
(en)
*
|
2002-01-23 |
2003-09-02 |
Debiopharm Sa |
Production of epi-hne-4 comprising reduction of improperly processed form
|
US20050222023A1
(en)
*
|
2002-02-07 |
2005-10-06 |
Hans-Peter Hauser |
Albumin-fused kunitz domain peptides
|
KR20040089608A
(ko)
*
|
2002-02-07 |
2004-10-21 |
델타 바이오테크놀로지 리미티드 |
Hiv 억제 단백질
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
JP2005534647A
(ja)
|
2002-06-07 |
2005-11-17 |
ダイアックス、コープ |
失血の予防及び軽減
|
US7153829B2
(en)
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
KR20050057047A
(ko)
*
|
2002-08-29 |
2005-06-16 |
제넨테크, 인크. |
아캐트-스큐트 유사-2 폴리펩티드 및 코딩 핵산 및 종양의진단 및 치료 방법
|
US6989369B2
(en)
*
|
2003-02-07 |
2006-01-24 |
Dyax Corp. |
Kunitz domain peptides
|
SI1641822T1
(sl)
|
2003-07-08 |
2013-08-30 |
Genentech, Inc. |
IL-17 A/F heterologni polipeptidi in njihove terapevtske uporabe
|
WO2005021556A2
(en)
*
|
2003-08-29 |
2005-03-10 |
Dyax Corp. |
Modified protease inhibitors
|
CA2536873C
(en)
*
|
2003-08-29 |
2019-09-10 |
Dyax Corp. |
Poly-pegylated protease inhibitors
|
CA2543360A1
(en)
*
|
2003-10-24 |
2005-05-06 |
Joost A. Kolkman |
Ldl receptor class a and egf domain monomers and multimers
|
EP1689432B1
(de)
|
2003-11-17 |
2009-12-30 |
Genentech, Inc. |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
EP1732593A1
(de)
*
|
2004-03-31 |
2006-12-20 |
Coloplast A/S |
Verwendung von epi-hne 1-4
|
EP1789453A2
(de)
*
|
2004-05-18 |
2007-05-30 |
Genentech, Inc. |
Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
|
EP1771212A1
(de)
*
|
2004-07-16 |
2007-04-11 |
Coloplast A/S |
Wundversorgungsvorrichtung
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
CA2587775A1
(en)
*
|
2004-11-22 |
2006-06-01 |
Dyax Corp. |
Plasmin-inhibitory therapies
|
WO2006091459A2
(en)
|
2005-02-24 |
2006-08-31 |
Joslin Diabetes Center, Inc. |
Compositions and methods for treating vascular permeability
|
CN101175769A
(zh)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
用于调控血管完整性的方法和组合物
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
JP2009501517A
(ja)
*
|
2005-07-13 |
2009-01-22 |
アムジェン マウンテン ビュー インコーポレイテッド |
Il−6結合タンパク質
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
GB0521404D0
(en)
*
|
2005-10-20 |
2005-11-30 |
Ares Trading Sa |
Kunitz domain containing protein
|
AU2006335053A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
CN105859886A
(zh)
|
2005-12-02 |
2016-08-17 |
健泰科生物技术公司 |
牵涉与il-22和il-22r结合的抗体的组合物和方法
|
SI1981519T1
(en)
|
2005-12-29 |
2018-05-31 |
Dyax Corp. |
INHIBITION PROTEAZE
|
JP5770966B2
(ja)
|
2005-12-29 |
2015-08-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Tfpi−2の変異体クニッツドメインiに関連した方法および組成物
|
CA2638821A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
EP2614839A3
(de)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
|
EP2082645A1
(de)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
|
WO2007134132A2
(en)
*
|
2006-05-12 |
2007-11-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
US8586006B2
(en)
|
2006-08-09 |
2013-11-19 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
US20100297103A1
(en)
|
2006-09-14 |
2010-11-25 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
US20100119512A1
(en)
*
|
2007-01-25 |
2010-05-13 |
Joslin Diabetes Center |
Methods of diagnosing, treating, and preventing increased vascular permeability
|
US7875431B2
(en)
|
2007-02-22 |
2011-01-25 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
US20090075887A1
(en)
*
|
2007-08-21 |
2009-03-19 |
Genzyme Corporation |
Treatment with Kallikrein Inhibitors
|
EP2205971A4
(de)
*
|
2007-10-04 |
2011-03-30 |
Bionomics Ltd |
Endothelzellen-marker und verwendungen davon
|
CN101186646B
(zh)
*
|
2007-10-26 |
2010-06-09 |
中国科学院昆明动物研究所 |
眼镜王蛇毒蛋白酶抑制剂及其衍生物的应用
|
SI2514436T1
(en)
|
2007-11-07 |
2018-04-30 |
Genentech, Inc. |
IL-22 for use in the treatment of microbial diseases
|
EP2319869B1
(de)
|
2008-06-20 |
2016-08-17 |
National University Corporation Okayama University |
ANTIKÖRPER GEGEN DEN OXIDIERTES LDL/ß²GPI-KOMPLEX UND ANWENDUNG DAVON
|
US9182406B2
(en)
*
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
SI2376535T1
(sl)
|
2008-12-09 |
2017-07-31 |
F. Hoffmann-La Roche Ag |
Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
|
EA201100943A1
(ru)
|
2008-12-16 |
2012-05-30 |
Новартис Аг |
Системы дрожжевого дисплея
|
SI2379096T1
(sl)
|
2008-12-19 |
2020-03-31 |
Baxalta GmbH |
Zaviralci TFPI in postopki uporabe
|
AU2010203712A1
(en)
*
|
2009-01-06 |
2010-07-15 |
Dyax Corp. |
Treatment of mucositis with kallikrein inhibitors
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
AR079217A1
(es)
|
2009-11-30 |
2012-01-04 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
SI2521568T1
(sl)
*
|
2010-01-06 |
2019-01-31 |
Dyax Corp. |
Proteini, ki vežejo plazemski kalikrein
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
MX2012009215A
(es)
|
2010-02-23 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
EP3146977A1
(de)
|
2010-03-19 |
2017-03-29 |
Baxalta GmbH |
Tfpi-hemmer und verfahren zur verwendung
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
CN103635489B
(zh)
|
2011-01-06 |
2016-04-13 |
戴埃克斯有限公司 |
血浆前激肽释放酶结合蛋白
|
WO2012129347A1
(en)
|
2011-03-21 |
2012-09-27 |
Biodesy, Llc |
Classification of kinase inhibitors using nonlinear optical techniques
|
WO2012142526A1
(en)
|
2011-04-14 |
2012-10-18 |
Modiano Jaime |
Use of tumor fas expression to determine response to anti-cancer therapy
|
TW201840336A
(zh)
|
2011-08-01 |
2018-11-16 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
|
KR20140068062A
(ko)
|
2011-09-15 |
2014-06-05 |
제넨테크, 인크. |
분화의 촉진 방법
|
KR20140084164A
(ko)
|
2011-10-15 |
2014-07-04 |
제넨테크, 인크. |
암의 치료를 위한 scd1 길항제
|
CN104168920A
(zh)
|
2012-01-18 |
2014-11-26 |
霍夫曼-拉罗奇有限公司 |
使用fgf19调控剂的方法
|
BR112014019741A2
(pt)
|
2012-02-11 |
2020-12-22 |
Genentech, Inc |
Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
MX2014010953A
(es)
|
2012-03-16 |
2014-10-13 |
Hoffmann La Roche |
Metodos para tratamiento de melanoma con inhibidores pak1.
|
KR20140142293A
(ko)
|
2012-03-16 |
2014-12-11 |
제넨테크, 인크. |
조작된 입체형태적으로-안정화된 단백질
|
NZ629130A
(en)
|
2012-03-21 |
2016-10-28 |
Baxalta Inc |
Tfpi inhibitors and methods of use
|
CN106290917B
(zh)
|
2012-04-25 |
2020-06-05 |
比奥德赛公司 |
用于检测蛋白质的变构调节剂的方法
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
EP3556776A1
(de)
|
2012-05-31 |
2019-10-23 |
F. Hoffmann-La Roche AG |
Verfahren zur krebsbehandlung unter verwendung von pd-1-achsen-bindungsantagonisten und vegf-antagonisten
|
EP2708235A1
(de)
*
|
2012-09-17 |
2014-03-19 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Peptidantagonisten des Vasopressin-2-Rezeptors
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
CA2905070A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
EP2972373B1
(de)
|
2013-03-15 |
2019-10-09 |
F.Hoffmann-La Roche Ag |
Biomarker und verfahren zur behandlung von pd-1 und pd-l1-verwandten leiden
|
TR201809571T4
(tr)
|
2013-03-15 |
2018-07-23 |
Hoffmann La Roche |
Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
|
KR20160030936A
(ko)
|
2013-07-16 |
2016-03-21 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
|
WO2015095410A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
AU2015218704B2
(en)
*
|
2014-02-24 |
2019-05-02 |
Takeda Gmbh |
UTI fusion proteins
|
CN106459210A
(zh)
|
2014-03-27 |
2017-02-22 |
戴埃克斯有限公司 |
用于治疗糖尿病黄斑性水肿的组合物和方法
|
CA3225091A1
(en)
|
2014-05-05 |
2015-11-12 |
Regeneron Pharmaceuticals, Inc. |
Humanized c5 and c3 animals
|
CN106661622B
(zh)
|
2014-05-23 |
2020-08-21 |
豪夫迈·罗氏有限公司 |
Mit生物标志物和使用它们的方法
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック, インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
US10562946B2
(en)
|
2014-06-20 |
2020-02-18 |
Genentech, Inc. |
Chagasin-based scaffold compositions, methods, and uses
|
AU2015289672A1
(en)
|
2014-07-15 |
2017-03-02 |
Genentech, Inc. |
Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors
|
US11219670B2
(en)
|
2014-09-05 |
2022-01-11 |
The Johns Hopkins University |
Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
|
BR112017010324A2
(pt)
|
2014-11-20 |
2018-05-15 |
F. Hoffmann-La Roche Ag |
método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
|
EP3227337A1
(de)
|
2014-12-05 |
2017-10-11 |
F. Hoffmann-La Roche AG |
Verfahren und zusammensetzungen zur krebsbehandlung mit pd-1-achsenantagonisten und hpk1-antagonisten
|
EP3237906B8
(de)
|
2014-12-23 |
2020-10-28 |
Bluelight Therapeutics, Inc. |
Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
|
US10376535B2
(en)
|
2015-03-26 |
2019-08-13 |
University Of Rochester |
Therapy for malignant disease
|
CN107787332B
(zh)
|
2015-04-24 |
2022-09-09 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
EP3718569B1
(de)
|
2015-05-22 |
2023-05-03 |
Translational Drug Development, LLC |
Benzamid- und aktivverbindungszusammensetzungen und verwendungsmethoden
|
WO2016205681A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
US20180282415A1
(en)
|
2015-09-30 |
2018-10-04 |
Merck Patent Gmbh |
Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
|
EP3371211A4
(de)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
|
EA201891388A1
(ru)
|
2015-12-11 |
2018-11-30 |
Дайэкс Корп. |
Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
|
EP3405478A4
(de)
|
2015-12-23 |
2019-10-30 |
Moonshot Pharma LLC |
Verfahren zur induzierung einer immunantwort durch hemmung von nonsense-vermitteltem zerfall
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
AU2017292646A1
(en)
|
2016-07-05 |
2019-02-07 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
JP2019534858A
(ja)
|
2016-09-09 |
2019-12-05 |
ジェネンテック, インコーポレイテッド |
Frizzledの選択的ペプチド阻害剤
|
EP3523294A4
(de)
|
2016-09-28 |
2021-01-13 |
Blade Therapeutics, Inc. |
Calpain-modulatoren und therapeutische verwendungen davon
|
CA3082255A1
(en)
|
2016-11-23 |
2020-06-10 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
AU2018225745B2
(en)
|
2017-02-27 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Humanized model of kidney and liver disorders
|
JP7248588B2
(ja)
|
2017-04-21 |
2023-03-29 |
ジェネンテック, インコーポレイテッド |
疾患の治療のためのklk5アンタゴニストの使用
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
JP2020525434A
(ja)
|
2017-06-22 |
2020-08-27 |
ムーンショット ファーマ エルエルシー |
アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和治疗乙肝病毒感染的抗体和方法
|
EP3728321A1
(de)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Verwendung von pilra-bindenden mitteln zur behandlung einer erkrankung
|
CN114555812A
(zh)
*
|
2019-04-17 |
2022-05-27 |
非凡食品有限公司 |
用于蛋白质产生的材料和方法
|
KR20220005568A
(ko)
|
2019-05-09 |
2022-01-13 |
제넨테크, 인크. |
항체의 제조 방법
|
EP3976090A1
(de)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Kombinationstherapien mit cdk-hemmern
|
BR112022017718A2
(pt)
|
2020-03-05 |
2022-11-16 |
Diamedica Usa Inc |
Polipeptídeos de ulinastatina
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
JP2023545566A
(ja)
|
2020-10-20 |
2023-10-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-1軸結合アンタゴニストとlrrk2阻害剤との併用療法
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
CN112940095B
(zh)
*
|
2021-02-07 |
2022-04-15 |
西南大学 |
家蚕BmSPI51突变蛋白BmSPI51M及其制备方法和应用
|
KR20240019109A
(ko)
|
2021-06-09 |
2024-02-14 |
에프. 호프만-라 로슈 아게 |
암의 치료에 이용하기 위한 특정 braf 억제제(패러독스 브레이크) 및 pd-1 축 결합 길항제의 조합물
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|